NEF505460_sm1.docx (19.83 kB)
Download file

Supplementary Material for: Lack of Association between Pretransplant Donor-Specific Antibodies and Posttransplant Kidney Outcomes in Simultaneous Liver-Kidney Transplant Recipients with Rabbit Anti-Thymocyte Globulin Induction and Steroid-Free Protocol

Download (19.83 kB)
posted on 31.01.2020, 12:09 by Yazawa M., Cseprekal O., Helmick R.A., Talwar M., Balaraman V., Podila P.S.B., Agbim U.A., Maliakkal B., Fossey S., Satapathy S.K., Sumida K., Kovesdy C.P., Nair S., Eason J.D., Molnar M.Z.
Introduction and Objective: The impact of pretransplant donor-specific antibodies (DSAs), especially class II DSAs, on kidney allograft outcomes remains unclear in simultaneous liver-kidney transplantation (SLKT) recipients. Methods: We examined 85 recipients who consecutively underwent SLKT between 2009 and 2018 in our center. Associations between pretransplant DSA and worsening kidney function (WKF), kidney allograft loss, composite kidney outcome (WKF and/or antibody-mediated rejection and/or death-censored kidney allograft loss), death with functioning graft, and overall mortality were examined in survival analysis. WKF was defined as an eGFR decrease of 30% or greater from baseline, or 2 or more episodes of proteinuria, at least 90 days apart from each other. Results: The mean age at SLKT was 56 ± 10 years, and 62% of the recipients were male. More than one quarter (26%) of our recipients were African American. The 2 major causes of end-stage liver disease were hepatitis C (28%) and alcoholic hepatitis (26%). Nineteen recipients (22%) had pretransplant DSAs at the time of SLKT. The DSA(+) group and DSA(−) group had similar risk of WKF (unadjusted model: hazard ratio [HR] = 0.77, 95% confidence interval [CI]: 0.29–2.05 and adjusted model: HR = 0.36, 95% CI: 0.12–1.08); similar risk of composite kidney outcome (unadjusted model: HR = 1.04, 95% CI: 0.45–2.43 and adjusted model: HR = 0.53, 95% CI: 0.20–1.39); and similar risk of overall death (unadjusted model: HR = 1.23, 95% CI: 0.45–3.36 and adjusted model: HR = 1.28, 95% CI: 0.42–3.87). We found similar results when comparing different DSA subclasses (class I and II DSAs) with recipients without DSAs. Conclusions: The presence of pretransplant DSAs was not associated with worse kidney allograft outcomes from our single-center experience. Further prospective larger studies are strongly warranted.